- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Kathleen Lokay on How Data Generation Informs Clinical Pathways
Digital utilization can generate data with supporting evidence for clinical pathways that benefits clinicians, explained Kathleen Lokay, president and CEO of Via Oncology.
Digital utilization can generate data with supporting evidence for clinical pathways that benefits clinicians, explained Kathleen Lokay, president and CEO of Via Oncology.
Transcript
How does digital data collection and utilization impact decision making for providers?
As I think about it in the light of clinical pathways, really the digital utilization of clinical pathways, helps the clinicians keep up with clinical evidence, pick treatments for their patients that are high value, really stay abreast of current information. The data generated from that is what is also interesting because then that data informs not only that the physicians was on or off pathway but actually helps the next iteration of that pathway.
So the committees who develop the pathways can learn from the data that is collected by utilizing the pathways so the decision support is actually then in the future really a contributor to the data because it informs whether or not the physicians felt that the pathway was adequate for the patients so it’s an inner cycle.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
